GLOBAL NETWORK OF BANGLADESHI BIOTECHNOLOGISTS

NEWS

FDA-Approved Recombinant DNA-based Technology Flu Vaccine more Effective than those currently available

FDA-Approved Recombinant DNA-based Technology Flu Vaccine more Effective than those currently available

In the weekly science magazine Nature a piece of breakthrough news has been published in its 18th Jan,  2013 issue that the U.S. Food and Drug Administration  (FDA) has approved a new seasonal influenza vaccine through the use of novel DNA recombinant technology.  The trivalent vaccine named Flublok  has been made for the prevention of seasonal influenza for 18-40 years old people . It was made using insect virus (baculovirus) expression system. Flublok contains three, full-length, recombinant hemagglutinin (HA)  proteins to help protect against two influenza virus A strains, H1N1 and H3N2, and one influenza virus B strain. A survey conducted on 2,300 people to a placebo group of similar size revealed that recombinant DNA based technology, Flublok was about 44.6 percent effective against all circulating influenza strains.

Recent News

Calendar

February 2017
Su Mo Tu We Th Fr Sa
29 30 31 1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 1 2 3